# mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

> **NCT07557602** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Vaccine Company, Inc.** · enrollment: 45 (estimated)

## Conditions studied

- EBV

## Interventions

- **BIOLOGICAL:** VXCO-102
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07557602
- **Lead sponsor:** Vaccine Company, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-04
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07557602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07557602, "mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07557602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*